End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
9,200 HUF | +1.38% | +3.90% | +5.14% |
Mar. 25 | Gedeon Richter Plc. Proposes Dividend | CI |
Feb. 29 | Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Its low valuation, with P/E ratio at 7.6 and 6.87 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- This company will be of major interest to investors in search of a high dividend stock.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Historically, the company has been releasing figures that are above expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+5.14% | 4.57B | B+ | ||
+20.81% | 43.34B | B- | ||
+20.44% | 21.96B | B+ | ||
+13.30% | 14.09B | - | ||
+12.97% | 13.64B | B+ | ||
+39.74% | 11.43B | B | ||
-8.59% | 6.86B | B+ | ||
-0.05% | 6.79B | - | - | |
-8.87% | 5.73B | - | - | |
+8.46% | 5.22B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- RICHTER Stock
- Ratings Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.